-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Background: Tenofovir disoproxil fumarate (TDF) combined with emtricitabine (FTC) is widely used in HIV treatment as part of combination antiretroviral therapy (cART) and HIV pre-exposure prevention (PrEP)
.
Although TDF is generally safe, it is related to kidney, endocrine, and osteotoxicity, including decreased glomerular filtration rate (GFR) and renal tubular dysfunction caused by the consumption of urine protein, glucose, and phosphate
Tenofovir disoproxil fumarate (TDF) combined with emtricitabine (FTC) is widely used in HIV treatment as part of combination antiretroviral therapy (cART) and HIV pre-exposure prevention (PrEP)
Result
.
The sample included 101 participants, with a mean age (SD) of 19.
In the 48-week study, compared with the low drug exposure group, the baseline and changes in metabolism and DXA measurements in the high drug exposure group
In the 48-week study, compared with the low drug exposure group, the baseline and changes in metabolism and DXA measurements in the high drug exposure groupConclusion: These findings support the short-term renal safety of HIV seronegative young men receiving TDF/FTC PrEP treatment, and suggest that endocrine disorders (PTH-FGF23) are the main cause of TDF-related bone mineral density decline in this age group
.
.
Original source
Havens PL, Stephensen CB, Van Loan MD,et al, Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Leave a message here
